Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with... Read More

Tuesday May 29, 2018 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rucaparib

Clovis Oncology offering convertible senior notes, stocks to raise up to $345M

Clovis Oncology offering convertible senior notes, stocks to raise up to $345M

BOULDER -- Clovis Oncology, Inc .(NASDAQ:CLVS) announced it has commenced two separate underwritten public offerings of convertible senior notes and common stock to raise a total of $345... Read More

Monday April 16, 2018 0 comments Tags: Boulder, Clovis Oncology, Rucaparib

Clovis: EU Medicines Agency approval sought for rucaparib cancer drug

Clovis: EU Medicines Agency approval sought for rucaparib cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Unions (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that... Read More

Tuesday December 19, 2017 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rucaparib

Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

BOULDER -- Clovis Oncology (NASDAQ: CLVS) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance... Read More

Tuesday October 10, 2017 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey, FDA

Clovis Oncology: Rucaparib improved survival in ovarian cancer patients

Clovis Oncology: Rucaparib improved survival in ovarian cancer patients

BOULDER -- ClovisOncology (NASDAQ: CLVS) today announced toplinedata from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achievedthe primary endpoint of improved... Read More

Monday June 19, 2017 0 comments Tags: Boulder, Clovis Oncology, Patrick Mahaffy, Rucaparib

Clovis announces FDA application for accelerated approval of cancer drug

Clovis announces FDA application for accelerated approval of cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the U.S. Food and Drug Administration (FDA) has accepted Clovis New Drug Application (NDA) for accelerated approval of rucaparib and... Read More

Thursday August 25, 2016 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy, Foundation Medicine

Clovis Oncology's rucaparib ovarian cancer drug granted FDA Breakthrough Therapy designation

Clovis Oncology's rucaparib ovarian cancer drug granted FDA Breakthrough Therapy designation

BOULDER Clovis Oncology Inc. (NASDAQ: CLVS) announced the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the companys investigational agent rucaparib as... Read More

By: InnovatioNews Tuesday April 7, 2015 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey

Clovis Oncology begins rucaparib phase 2 clinical study with dosing of first patient at a U.S. site

Clovis Oncology begins rucaparib phase 2 clinical study with dosing of first patient at a U.S. site

BOULDER - Clovis Oncology, Inc . (NASDAQ: CLVS) today announced its Rucaparib Assessment in BRCA-mutated Pancreatic Cancer (RUCPANC) study has begun with the dosing of the first patient at a... Read More

By: InnovatioNews Monday June 16, 2014 0 comments Tags: Boulder, Clovis Oncology, Patrick J.Mahaffy, Rucaparib, RUPANC Phase 2, Susan Domchek